Spero Therapeutics (NASDAQ:SPRO) is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.
The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens. In parallel, Spero is advancing SPR720, an oral investigational agent targeting nontuberculous mycobacterial lung infections, and SPR206, a polymyxin derivative intended for intravenous use against a broad spectrum of Gram‐negative bacteria. Together, these programs seek to offer new options where few effective treatments currently exist.
Spero conducts clinical trials in North America and internationally, collaborating with academic institutions, hospitals and health authorities to evaluate safety and efficacy across diverse patient populations. The company’s efforts are supported by partnerships with research organizations and regulatory agencies, reflecting a commitment to global health initiatives aimed at reducing the burden of antimicrobial resistance.
Under the leadership of President and Chief Executive Officer Ankit Mahadevia, M.D., Spero Therapeutics leverages experience in infectious disease drug development and regulatory strategy. The management team and board of directors include seasoned professionals from both pharmaceutical and biotechnology industries, guiding the company through late‐stage clinical development and toward potential regulatory approvals and commercialization.
